摘要
为探讨紫杉醇联合卡铂化疗治疗宫颈癌的临床疗效,选择本院2018年12月至2020年12月收治的90例确诊宫颈癌患者术进行临床试验,并将其随机均分为对照组与治疗组,每组各45例。其中,对照组患者行紫杉醇联合顺铂静脉化疗进行治疗;治疗组患者行紫杉醇联合卡铂静脉化疗,对比观察两组患者的化疗前后肿瘤体积的变化、手术切除率和盆腔淋巴结转移情况。术前行紫杉醇联合卡铂化疗方案的治疗组患者的治疗总有效率高达82.22%,采取紫杉醇联合顺铂化疗方案的对照组总有效率仅57.78%,两组患者临床效果差异明显,P<0.05。两组患者联合化疗后影像学检查测得肿瘤最大直径均有所缩小,且治疗组化疗后肿瘤最大直径平均值(2.57±0.32)cm较对照组(4.01±0.28)cm更小,P<0.05。对照组患者的毒副反应显著强于治疗组,P<0.05;治疗组综合术后病理检查结果较对照组更优,达到病理完全缓解高达22例,对照组仅16例,P<0.05。采取紫杉醇联合卡铂方案行术前新辅助化疗,对局部晚期宫颈癌近期疗效显著,可缩小癌肿体积,提高手术中的肿瘤切除率,安全有效,值得临床推广。
To explore the clinical efficacy of paclitaxel combined with carboplatin chemotherapy in the treatment of cervical cancer,the 90 patients with confirmed cervical cancer admitted to the authors′hospital from December 2018 to December 2020 were selected for clinical trials.They were randomly divided into two groups with 45 cases in each group.Among them,patients in the control group were treated with paclitaxel combined with cisplatin intravenous chemotherapy;Patients in the treatment group were treated with paclitaxel combined with carboplatin intravenous chemotherapy.The changes in tumor volume,surgical resection rate and pelvic lymph node metastasis of the two groups were compared before and after chemotherapy.The total effective rate of patients in the treatment group who received paclitaxel combined with carboplatin chemotherapy before surgery was as high as 82.22%,and the total effective rate of the control group who took paclitaxel combined with cisplatin chemotherapy was only 57.78%.The clinical effects of the two groups were significantly different,P<0.05.The maximum diameter of the tumors in the two groups of patients after combined chemotherapy was reduced,and the average maximum diameter of the tumor after chemotherapy in the treatment group(2.57±0.32)cm was smaller than that of the control group(4.01±0.28)cm,P<0.05.The side effects of patients in the control group were significantly stronger than those in the treatment group,P<0.05.The comprehensive postoperative pathological examination results of the treatment group were better than those of the control group,achieving complete pathological remission as high as 22 cases,while the control group had only 16 cases,P<0.05.Preoperative neoadjuvant chemotherapy with paclitaxel combined with carboplatin has a significant short-term effect on locally advanced cervical cancer.It can reduce the size of the cancer and increase the tumor resection rate during surgery.It is safe and effective,and is worthy of clinical promotion.
作者
林鸿珠
黄永群
黄润强
王昌武
LIN Hong-zhu;HUANG Yong-qun;HUANG Run-qiang;WANG Chang-wu(Department of Obstetrics and Gynecology,People′s Hospital of Ledong Li Autonomous County,Ledong 572500,China;Department of Obstetrics and Gynecology,Fifth People′s Hospital of Hainan Province,Haikou 571199,China;Department of Obstetrics and Gynecology,Taihe Hospital,Hubei Medical College,Shiyan 442000,China;Department of Anesthesiology,People′s Hospital of Ledong Li Autonomous County,Ledong 572500,China)
出处
《药物生物技术》
CAS
2022年第1期58-62,共5页
Pharmaceutical Biotechnology
基金
海南省自然科学基金面上项目(No.817362)。
关键词
紫杉醇
卡铂
宫颈癌
肿瘤
化疗
安全性
Paclitaxel
Carboplatin
Cervical cancer
Tumor
Chemotherapy
Safety
